Mabwell's Adalimumab Biosimilar Receives Marketing Approval in Indonesia
PR Newswire —
SHANGHAI, Dec. 31, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its Adalimumab Injection 9MW0113 (Marketed as JUNMAIKANG in China) has been granted marketing authorization by the Indonesian...